Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378508 | 0.86 | P2RX7 (0.41) | MC4RP2RX7BRD4BRD9TEK | |
| SCHEMBL3128000 | 0.84 | CYP19A1 (0.47) | CYP19A1MC4RPTGDR2 | |
| SCHEMBL28263864 | 0.77 | CYP19A1 (0.68) | CYP19A1PTGDR2 | |
| SCHEMBL29471948 | 0.75 | CYP19A1 (0.54) | CYP19A1MAOAMAOB | |
| SCHEMBL29471949 | 0.73 | AGXT (0.52) | CYP19A1MAOAMAOB | |
| SCHEMBL14857886 | 0.73 | BRD4 (0.45) | P2RX7BRD4BRD9SCN2ASCN10A | |
| SCHEMBL6703722 | 0.72 | LMNA (0.48) | P2RX7BRD4BRD9CYP2A13PKM | |
| SCHEMBL6509065 | 0.72 | PKM (0.60) | BRD4BRD9CYP2A13PKM | |
| SCHEMBL10210890 | 0.72 | CYP2A13 (0.53) | PDE2ACYP2A13 | |
| SCHEMBL3127155 | 0.71 | BRD4 (0.53) | P2RX7BRD4BRD9SCN2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | CYP19A1 1469/4885MC4R 2358/4885P2RX7 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.